RU2009128690A - NEW SUBSTITUTED DERIVATIVES OF Isoquinoline and Isoquinolinone - Google Patents
NEW SUBSTITUTED DERIVATIVES OF Isoquinoline and Isoquinolinone Download PDFInfo
- Publication number
- RU2009128690A RU2009128690A RU2009128690/04A RU2009128690A RU2009128690A RU 2009128690 A RU2009128690 A RU 2009128690A RU 2009128690/04 A RU2009128690/04 A RU 2009128690/04A RU 2009128690 A RU2009128690 A RU 2009128690A RU 2009128690 A RU2009128690 A RU 2009128690A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- alkylene
- aryl
- compound according
- isoquinolin
- Prior art date
Links
- 0 CC(C*1C)**(*)CCC1(C)Ic1c(*)c(*)c(c(*)nc(*)c2*)c2c1* Chemical compound CC(C*1C)**(*)CCC1(C)Ic1c(*)c(*)c(c(*)nc(*)c2*)c2c1* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
Abstract
1. Соединение формулы (I) !! в которой R1 представляет собой H, OH или NH2; ! R2 представляет собой ! R', ! (C7-C8)алкил, ! (C1-C6)алкилен-R', ! (C2-C6)алкенил, ! (C2-C6)алкинил, ! (C1-C6)алкилен-O-R', ! (C1-C6)алкилен-CH[R']2, ! (C1-C6)алкилен-C(O)-R', ! (C1-C6)алкилен-C(O)NH2, ! (C1-C6)алкилен-C(O)NH-R', ! (C1-C6)алкилен-C(O)NH-(C1-C6)алкил, ! (C1-C6)алкилен-C(O)N[(C1-C6)алкил]2, ! (C1-C6)алкилен-C(O)N[R']2, ! (C1-C6)алкилен-C(O)O-(C1-C6)алкил, ! C(O)O-(C1-C6)алкил, ! C(O)OR', ! C(O)(C1-C6)алкил, ! C(O)R', ! C(O)NH-(C1-C6)алкил, ! C(O)NHR', ! C(O)-NH(C2-C6)алкенил, ! C(O)-NH(C2-C6)алкинил, ! C(O)-NH(C1-C6)алкилен-R', ! C(O)N[(C1-C6)алкил]R', ! C(O)N[(C1-C6)алкил]2, ! C(O)-(C1-C6)алкилен-R', ! C(O)O(C1-C6)алкилен-R'; ! или R2 представляет собой (C1-C6)алкил при условии, что в указанном алкильном остатке по меньшей мере один атом водорода замещен OH, OCH3, COOH, COOCH3, NH2, NHCH3, N(CH3)2, CONH2, CONHCH3 или CON(CH3)2; ! или R2 представляет собой (C1-C4)алкилен, связанный с циклическим амином, в котором данный (C1-C4)алкилен образует вторую связь с другим атомом углерода циклического аминного цикла и образует вместе с атомами углерода циклического амина второй 4-8-членный цикл; ! R3 представляет собой ! H, ! галоген, ! (C1-C6)алкил, ! (C1-C6)алкилен-R', ! OH, ! O-R'', ! NH2, ! NHR'', ! NR''R'' или ! NH-C(O)-R'', ! R4 представляет собой ! H, ! галоген, ! гидрокси, ! CN, ! (C1-C6)алкил, ! R', ! (C1-C6)алкилен-R'; ! R5 представляет собой ! H, ! галоген, ! CN, ! NO2, ! (C1-C6)алкил, ! (C2-C6)алкенил, ! R', ! (C1-C6)алкилен-(C6-C10)арил, ! (C1-C6)алкенилен-(C6-C10)арил, ! (C1-C6)алкилен-(C5-C10)гетероциклил, ! CH(OH)-(C1-C6)алкил, ! NH2, ! NH-R', ! NH-SO2H, ! NH-SO2-(C1-C6)алкил, ! NH-SO2-R', !NH-C(O)-(C1-C6)алкил, ! NH-C(O)-R', ! C(O)N[(C1-C6)алкил]2, ! C(O)OH или ! C(O)O-(C1-C6)алкил; ! R6 представляет собой ! H, ! R', ! (C1-C8)алкил, ! (C1-C6)алкилен-R', ! (C1-C6)алкилен-O-(C1-C6)алкил, ! (C1-C6)алкилен-O-R', ! (C1-C6)алкилен-CH[R']2, ! (C1-C6)алкилен-C(O)-R', ! (C1-C6)алкилен-C(O)NH2, ! (C1-C6)алкилен-C(O)NH-R', ! (C1-C6)алкилен-C(O)NH-(C1-C6)алкил, ! (C1-C6)алки 1. The compound of formula (I) !! in which R1 represents H, OH or NH2; ! R2 is! R ',! (C7-C8) alkyl,! (C1-C6) alkylene-R ',! (C2-C6) alkenyl,! (C2-C6) alkynyl,! (C1-C6) alkylene-O-R ',! (C1-C6) alkylene-CH [R '] 2,! (C1-C6) alkylene-C (O) -R ',! (C1-C6) alkylene-C (O) NH2,! (C1-C6) alkylene-C (O) NH-R ',! (C1-C6) alkylene-C (O) NH- (C1-C6) alkyl,! (C1-C6) alkylene-C (O) N [(C1-C6) alkyl] 2,! (C1-C6) alkylene-C (O) N [R '] 2,! (C1-C6) alkylene-C (O) O- (C1-C6) alkyl,! C (O) O- (C1-C6) alkyl,! C (O) OR ',! C (O) (C1-C6) alkyl,! C (O) R ',! C (O) NH- (C1-C6) alkyl,! C (O) NHR ',! C (O) -NH (C2-C6) alkenyl,! C (O) -NH (C2-C6) alkynyl,! C (O) -NH (C1-C6) alkylene-R ',! C (O) N [(C1-C6) alkyl] R ',! C (O) N [(C1-C6) alkyl] 2,! C (O) - (C1-C6) alkylene-R ',! C (O) O (C1-C6) alkylene-R '; ! or R2 is (C1-C6) alkyl, provided that at least one hydrogen atom in said alkyl radical is substituted with OH, OCH3, COOH, COOCH3, NH2, NHCH3, N (CH3) 2, CONH2, CONHCH3 or CON (CH3 ) 2; ! or R2 is a (C1-C4) alkylene bound to a cyclic amine in which this (C1-C4) alkylene forms a second bond with another carbon atom of the cyclic amine ring and forms a second 4-8 membered ring together with the carbon atoms of the cyclic amine ; ! R3 represents! H,! halogen! (C1-C6) alkyl,! (C1-C6) alkylene-R ',! OH,! O-R '',! NH2,! NHR '',! NR``R '' or! NH-C (O) -R '',! R4 represents! H,! halogen! hydroxy,! CN,! (C1-C6) alkyl,! R ',! (C1-C6) alkylene-R '; ! R5 represents! H,! halogen! CN,! NO2,! (C1-C6) alkyl,! (C2-C6) alkenyl,! R ',! (C1-C6) alkylene- (C6-C10) aryl,! (C1-C6) alkenylene- (C6-C10) aryl,! (C1-C6) alkylene- (C5-C10) heterocyclyl,! CH (OH) - (C1-C6) alkyl,! NH2,! NH-R ',! NH-SO2H,! NH-SO2- (C1-C6) alkyl,! NH-SO2-R ',! NH-C (O) - (C1-C6) alkyl,! NH-C (O) -R ',! C (O) N [(C1-C6) alkyl] 2,! C (O) OH or! C (O) O- (C1-C6) alkyl; ! R6 represents! H,! R ',! (C1-C8) alkyl,! (C1-C6) alkylene-R ',! (C1-C6) alkylene-O- (C1-C6) alkyl,! (C1-C6) alkylene-O-R ',! (C1-C6) alkylene-CH [R '] 2,! (C1-C6) alkylene-C (O) -R ',! (C1-C6) alkylene-C (O) NH2,! (C1-C6) alkylene-C (O) NH-R ',! (C1-C6) alkylene-C (O) NH- (C1-C6) alkyl,! (C1-C6) alkyl
Claims (57)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06026892.7 | 2006-12-27 | ||
EP06026892 | 2006-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2009128690A true RU2009128690A (en) | 2011-02-10 |
Family
ID=38015325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009128690/04A RU2009128690A (en) | 2006-12-27 | 2007-12-19 | NEW SUBSTITUTED DERIVATIVES OF Isoquinoline and Isoquinolinone |
Country Status (30)
Country | Link |
---|---|
US (1) | US8772492B2 (en) |
EP (1) | EP2132194B1 (en) |
JP (1) | JP5313919B2 (en) |
KR (1) | KR101545533B1 (en) |
CN (1) | CN101573354B (en) |
AR (1) | AR064493A1 (en) |
AT (1) | ATE502027T1 (en) |
AU (1) | AU2007338411B2 (en) |
BR (1) | BRPI0720909A2 (en) |
CA (1) | CA2673921C (en) |
CL (1) | CL2007003819A1 (en) |
CO (1) | CO6210690A2 (en) |
CR (1) | CR10815A (en) |
DE (1) | DE602007013295D1 (en) |
DK (1) | DK2132194T3 (en) |
EC (1) | ECSP099469A (en) |
ES (1) | ES2363105T3 (en) |
IL (1) | IL199538A (en) |
MA (1) | MA31024B1 (en) |
MX (1) | MX2009005862A (en) |
MY (1) | MY148902A (en) |
NI (1) | NI200900109A (en) |
NO (1) | NO20092434L (en) |
PT (1) | PT2132194E (en) |
RU (1) | RU2009128690A (en) |
SV (1) | SV2009003316A (en) |
TN (1) | TN2009000273A1 (en) |
TW (1) | TWI448286B (en) |
WO (1) | WO2008077555A2 (en) |
ZA (1) | ZA200903554B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2619129C2 (en) * | 2011-07-08 | 2017-05-12 | Санофи | Crystalline solvates of hydrochloride 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2611295C (en) | 2005-06-28 | 2014-04-22 | Sanofi-Aventis | Isoquinoline derivatives as inhibitors of rho-kinase |
ES2580108T3 (en) | 2005-07-11 | 2016-08-19 | Aerie Pharmaceuticals, Inc | Isoquinoline compounds |
CA2615577C (en) | 2005-07-26 | 2014-09-09 | Sanofi-Aventis | Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors |
EP1912949B1 (en) | 2005-07-26 | 2011-08-24 | Sanofi | Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors |
JP5235887B2 (en) | 2006-09-20 | 2013-07-10 | アエリー ファーマシューティカルズ インコーポレイテッド | Rho kinase inhibitor |
ES2363105T3 (en) | 2006-12-27 | 2011-07-20 | Sanofi-Aventis | SUBSTITUTED ISOQUINOLINS AND ITS USE AS INHIBITORS OF RHO-QUINASA. |
MX2009006517A (en) | 2006-12-27 | 2009-06-26 | Sanofi Aventis | Substituted isoquinoline and isoquinolinone derivatives. |
WO2008077554A1 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline derivatives |
WO2008077551A1 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Cycloalkylamine substituted isoquinolone derivatives |
AU2007338406B2 (en) | 2006-12-27 | 2012-08-09 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of Rho-kinase |
CN101578266B (en) | 2006-12-27 | 2013-10-30 | 塞诺菲-安万特股份有限公司 | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
NZ590070A (en) | 2008-06-24 | 2012-02-24 | Sanofi Aventis | Substituted isoquinolines and isoquinolinones as rho kinase inhibitors |
BRPI0914735A2 (en) | 2008-06-24 | 2019-09-24 | Sanofi Aventis | 6-substituted isoquinolines and isoquinolinones |
SI2303845T1 (en) * | 2008-06-24 | 2013-12-31 | Sanofi | Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
AU2009305624A1 (en) * | 2008-10-17 | 2010-04-22 | Exelixis, Inc. | Sphingosine-1-phosphate receptor antagonists |
CA2929545C (en) | 2009-05-01 | 2019-04-09 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
MX2012004289A (en) * | 2009-10-13 | 2012-06-12 | Msd Oss Bv | Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor. |
CN102993178A (en) * | 2012-12-04 | 2013-03-27 | 天津红日药业股份有限公司 | Isoquinoline compound with Rho kinase inhibition activity and preparation method and application thereof |
TWI647220B (en) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | Heteroaryl compound and its use |
ES2852377T3 (en) | 2013-03-15 | 2021-09-13 | Aerie Pharmaceuticals Inc | Dimesylate salts of 4- (3-amino-1- (isoquinolin-6-ylamino) -1-oxopropan-2-yl) benzyl, their combinations with prostaglandins and their use in the treatment of eye disorders |
MY181020A (en) * | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
AU2014228746B2 (en) * | 2013-03-15 | 2018-08-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
CN112538467A (en) | 2014-01-31 | 2021-03-23 | 株式会社Api | Percocylic acid 4-position hydroxylase and method for producing 4-hydroxyamino acid using same |
FR3017868A1 (en) | 2014-02-21 | 2015-08-28 | Servier Lab | ISOQUINOLINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
CN107532185B (en) | 2015-10-02 | 2023-01-06 | 株式会社Api | Process for producing hydroxy-L-pipecolic acid |
CN108601355B (en) | 2015-11-17 | 2021-03-30 | 爱瑞制药公司 | Process for preparing kinase inhibitors and intermediates thereof |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
WO2018045091A1 (en) | 2016-08-31 | 2018-03-08 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
CA3057872A1 (en) | 2017-03-31 | 2018-10-04 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2485537B2 (en) | 1977-04-13 | 1986-05-16 | Anvar | DIPYRIDO (4,3-B) (3,4-F) INDOLES, PROCESS FOR OBTAINING IT, THERAPEUTIC APPLICATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
EP0541559A1 (en) | 1990-07-31 | 1993-05-19 | E.I. Du Pont De Nemours And Company | Catalytic equilibration of selected halocarbons |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
NZ334613A (en) | 1996-08-12 | 2002-02-01 | Welfide Corp | Pharmaceutical agents comprising Rho kinase inhibitor |
JPH1087629A (en) | 1996-09-18 | 1998-04-07 | Fujisawa Pharmaceut Co Ltd | New isoquinoline derivative, and its medicinal use |
EP1007525A1 (en) | 1997-08-29 | 2000-06-14 | Zeneca Limited | Aminometyl oxooxazolidinyl benzene derivatives |
TW575567B (en) | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
GB9912701D0 (en) | 1999-06-01 | 1999-08-04 | Smithkline Beecham Plc | Novel compounds |
US6541456B1 (en) | 1999-12-01 | 2003-04-01 | Isis Pharmaceuticals, Inc. | Antimicrobial 2-deoxystreptamine compounds |
WO2001053288A1 (en) | 2000-01-20 | 2001-07-26 | Eisai Co., Ltd. | Novel piperidine compounds and drugs containing the same |
US7217722B2 (en) * | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
WO2001064238A2 (en) | 2000-02-29 | 2001-09-07 | Curis, Inc. | Methods and compositions for regulating adipocytes |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
AR033517A1 (en) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | PIPERIDINE DERIVATIVES, PROCESS FOR THE PREPARATION AND USE OF THESE DERIVATIVES IN THE MANUFACTURE OF MEDICINES |
GB0013060D0 (en) | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
WO2002034712A1 (en) | 2000-10-27 | 2002-05-02 | Takeda Chemical Industries, Ltd. | Process for preparing substituted aromatic compounds and intermediates therefor |
JP2004520347A (en) | 2001-01-15 | 2004-07-08 | グラクソ グループ リミテッド | Arylpiperidine and piperazine derivatives as inducers of LDL-receptor expression |
SE0101038D0 (en) | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
WO2002088101A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
WO2002100833A1 (en) * | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Rho KINASE INHIBITORS |
GB0117899D0 (en) | 2001-07-23 | 2001-09-12 | Astrazeneca Ab | Chemical compounds |
WO2003024450A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
SE0104340D0 (en) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
JPWO2004009555A1 (en) * | 2002-07-22 | 2005-11-17 | 旭化成ファーマ株式会社 | 5-substituted isoquinoline derivatives |
AU2003264427A1 (en) * | 2002-09-12 | 2004-04-30 | Kirin Beer Kabushiki Kaisha | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
WO2004105757A2 (en) | 2003-05-29 | 2004-12-09 | Schering Aktiengesellschaft | Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
WO2004113297A2 (en) | 2003-06-24 | 2004-12-29 | Neurosearch A/S | Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
EP1667982B1 (en) | 2003-09-23 | 2013-07-31 | Merck Sharp & Dohme Corp. | Isoquinolinone potassium channel inhibitors |
WO2005030130A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Isoquinoline potassium channel inhibitors |
US20050067037A1 (en) | 2003-09-30 | 2005-03-31 | Conocophillips Company | Collapse resistant composite riser |
WO2005035516A1 (en) | 2003-10-10 | 2005-04-21 | Ono Pharmaceutical Co., Ltd. | Novel fused heterocyclic compound and use thereof |
US7449477B2 (en) | 2003-11-25 | 2008-11-11 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) |
JP2005232175A (en) * | 2004-01-21 | 2005-09-02 | Asahi Kasei Pharma Kk | 5-substituted isoquinoline as medicine |
WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
EP1729761A4 (en) | 2004-03-05 | 2008-09-03 | Eisai Co Ltd | Cadasil treatment with cholinesterase inhibitors |
SE0400850D0 (en) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
US7517991B2 (en) | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
CA2611295C (en) * | 2005-06-28 | 2014-04-22 | Sanofi-Aventis | Isoquinoline derivatives as inhibitors of rho-kinase |
EP1912949B1 (en) | 2005-07-26 | 2011-08-24 | Sanofi | Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors |
CA2615577C (en) | 2005-07-26 | 2014-09-09 | Sanofi-Aventis | Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors |
TW200745101A (en) * | 2005-09-30 | 2007-12-16 | Organon Nv | 9-Azabicyclo[3.3.1]nonane derivatives |
US7618985B2 (en) | 2005-12-08 | 2009-11-17 | N.V. Organon | Isoquinoline derivatives |
TW200738682A (en) | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
US7893088B2 (en) | 2006-08-18 | 2011-02-22 | N.V. Organon | 6-substituted isoquinoline derivatives |
CN101578266B (en) | 2006-12-27 | 2013-10-30 | 塞诺菲-安万特股份有限公司 | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives |
ES2363105T3 (en) | 2006-12-27 | 2011-07-20 | Sanofi-Aventis | SUBSTITUTED ISOQUINOLINS AND ITS USE AS INHIBITORS OF RHO-QUINASA. |
-
2007
- 2007-12-19 ES ES07856891T patent/ES2363105T3/en active Active
- 2007-12-19 BR BRPI0720909A patent/BRPI0720909A2/en not_active IP Right Cessation
- 2007-12-19 MX MX2009005862A patent/MX2009005862A/en active IP Right Grant
- 2007-12-19 CA CA2673921A patent/CA2673921C/en not_active Expired - Fee Related
- 2007-12-19 PT PT07856891T patent/PT2132194E/en unknown
- 2007-12-19 WO PCT/EP2007/011168 patent/WO2008077555A2/en active Application Filing
- 2007-12-19 EP EP07856891A patent/EP2132194B1/en active Active
- 2007-12-19 DE DE602007013295T patent/DE602007013295D1/en active Active
- 2007-12-19 KR KR1020097013326A patent/KR101545533B1/en not_active IP Right Cessation
- 2007-12-19 AU AU2007338411A patent/AU2007338411B2/en not_active Ceased
- 2007-12-19 JP JP2009543376A patent/JP5313919B2/en not_active Expired - Fee Related
- 2007-12-19 MY MYPI20092542A patent/MY148902A/en unknown
- 2007-12-19 CN CN200780048335.9A patent/CN101573354B/en not_active Expired - Fee Related
- 2007-12-19 DK DK07856891.2T patent/DK2132194T3/en active
- 2007-12-19 RU RU2009128690/04A patent/RU2009128690A/en not_active Application Discontinuation
- 2007-12-19 AT AT07856891T patent/ATE502027T1/en active
- 2007-12-21 AR ARP070105858A patent/AR064493A1/en unknown
- 2007-12-25 TW TW096149802A patent/TWI448286B/en not_active IP Right Cessation
- 2007-12-26 CL CL200703819A patent/CL2007003819A1/en unknown
-
2009
- 2009-05-20 CR CR10815A patent/CR10815A/en not_active Application Discontinuation
- 2009-05-22 ZA ZA200903554A patent/ZA200903554B/en unknown
- 2009-06-02 NI NI200900109A patent/NI200900109A/en unknown
- 2009-06-12 CO CO09061598A patent/CO6210690A2/en not_active Application Discontinuation
- 2009-06-18 US US12/487,409 patent/US8772492B2/en not_active Expired - Fee Related
- 2009-06-24 IL IL199538A patent/IL199538A/en active IP Right Grant
- 2009-06-24 MA MA32039A patent/MA31024B1/en unknown
- 2009-06-24 SV SV2009003316A patent/SV2009003316A/en unknown
- 2009-06-26 EC EC2009009469A patent/ECSP099469A/en unknown
- 2009-06-26 NO NO20092434A patent/NO20092434L/en not_active Application Discontinuation
- 2009-06-26 TN TNP2009000273A patent/TN2009000273A1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2619129C2 (en) * | 2011-07-08 | 2017-05-12 | Санофи | Crystalline solvates of hydrochloride 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2009128690A (en) | NEW SUBSTITUTED DERIVATIVES OF Isoquinoline and Isoquinolinone | |
RU2009128653A (en) | Isoquinolone derivatives substituted by cycloalkylamine | |
RU2009128693A (en) | SUBSTITUTED DERIVATIVES OF Isoquinoline and Isoquinolinone | |
RU2009128652A (en) | Isoquinoline and isoquinolinone Substituted Cycloalkylamine Derivatives | |
RU2009128645A (en) | SUBSTITUTED ISOCHINOLINE AND ISOQUINOLINE DERIVATIVES AS RHO KINASE INHIBITORS | |
RU2009128688A (en) | Isoquinoline and isoquinolinone Substituted Cycloalkylamine Derivatives | |
RU2008102968A (en) | Isoquinoline Derivatives as RHO Kinase Inhibitors | |
RU2008106926A (en) | Cyclohexylaminoisoquinolone Derivatives as RHO Kinase Inhibitors | |
JP2010514720A5 (en) | ||
RU2008106950A (en) | PIPERIDINYL SUBSTITUTED ISOCHINOLONE DERIVATIVES AS RHO KINASE INHIBITORS | |
JP2010514721A5 (en) | ||
JP2009502829A5 (en) | ||
RU2011102456A (en) | SUBSTITUTED ICHIQUINOLINS AND Isoquinolinones AS INHIBITORS | |
JP2010514716A5 (en) | ||
IL275348B2 (en) | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists | |
JP2010514719A5 (en) | ||
JP2010514718A5 (en) | ||
JP2019501222A5 (en) | ||
RU2008129638A (en) | Pyrazine derivatives as an epithelial sodium channel blocker | |
AR080765A1 (en) | DERIVED FROM PIRIDINE AND PIRAZINE FOR THE TREATMENT OF CHYSICAL FIBROSIS (CF) | |
JP2010514717A5 (en) | ||
RU2008108477A (en) | NEW ANTIBACTERIAL COMPOUNDS | |
JP2008526999A5 (en) | ||
IS7709A (en) | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | |
CA2044748A1 (en) | Pyrazolopyrimidinone antianginal agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110311 |